LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Rhea-AI Summary

LAVA Therapeutics (Nasdaq: LVTX) announced that Stephen Hurly, CEO, will participate in a fireside chat at the UBS Global Healthcare Conference 2022.

Event Details:

• Date: May 23, 2022
• Time: 4:15-4:45 PM ET

A live webcast and replay will be available on the company's investor relations website. LAVA Therapeutics focuses on developing its proprietary Gammabody™ platform targeting cancer treatment.

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.

Presentation Details
Format: Fireside chat
Date: Monday, May 23, 2022
Time: 4:15-4:45p.m. ET.

A live webcast of the fireside chat and a replay of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.

About LAVA Therapeutics
LAVA Therapeutics N.V. is an immuno-oncology company utilizing its proprietary Gammabody™ platform  to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

 

FAQ

What date will LAVA Therapeutics participate in the UBS Global Healthcare Conference 2022?

LAVA Therapeutics will participate in the UBS Global Healthcare Conference on May 23, 2022.

Who will represent LAVA Therapeutics at the UBS Global Healthcare Conference?

Stephen Hurly, the CEO of LAVA Therapeutics, will represent the company at the conference.

What is the time for LAVA Therapeutics' presentation at the UBS conference?

The presentation will take place from 4:15 to 4:45 PM ET.

How can I access the webcast of LAVA Therapeutics' conference presentation?

The webcast can be accessed on the LAVA Therapeutics investor relations website under the 'Events' tab.

What is the focus of LAVA Therapeutics?

LAVA Therapeutics focuses on developing bispecific gamma delta T cell engagers using its Gammabody™ platform for cancer treatment.